Cargando…

Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines

Tumor dissemination and recurrence is attributed to highly resistant cancer stem cells (CSCs) which may constitute a fraction of circulating tumor cells (CTCs). Small cell lung cancer (SCLC) constitutes a suitable model to investigate the relation of CTCs and CSCs due to rapid tumor spread and a hig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hochmair, Maximilian, Rath, Barbara, Klameth, Lukas, Ulsperger, Ernst, Weinlinger, Christoph, Fazekas, Andreas, Plangger, Adelina, Zeillinger, Robert, Hamilton, Gerhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Preclinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340652/ https://www.ncbi.nlm.nih.gov/pubmed/31446534 http://dx.doi.org/10.1007/s10637-019-00847-8

Ejemplares similares

Expression of Proteolytic Enzymes by Small Cell Lung Cancer Circulating Tumor Cell Lines
por: Rath, Barbara, et al.
Publicado: (2019)

Small cell lung cancer: circulating tumor cell lines and expression of mediators of angiogenesis and coagulation
por: Rath, Barbara, et al.
Publicado: (2023)

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
por: Plangger, Adelina, et al.
Publicado: (2021)

Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines
por: Rath, Barbara, et al.
Publicado: (2018)

Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance
por: Klameth, Lukas, et al.
Publicado: (2017)

Receptor tyrosine kinase expression of circulating tumor cells in small cell lung cancer
por: Hamilton, Gerhard, et al.
Publicado: (2015)

Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells
por: Plangger, Adelina, et al.
Publicado: (2021)

Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
por: Rath, Barbara, et al.
Publicado: (2020)

How to target small cell lung cancer
por: Hamilton, Gerhard, et al.
Publicado: (2015)

Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer
por: Obermayr, Eva, et al.
Publicado: (2019)

Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
por: Obermayr, Eva, et al.
Publicado: (2021)

Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines
por: Hamilton, Gerhard, et al.
Publicado: (2014)

Changes of protein expression during tumorosphere formation of small cell lung cancer circulating tumor cells
por: STICKLER, SANDRA, et al.
Publicado: (2023)

Resistance to chemoimmunotherapy in non-small-cell lung cancer
por: Hochmair, Maximilian Johannes
Publicado: (2020)

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2019)

Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines
por: Plangger, Adelina, et al.
Publicado: (2022)

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
por: Proia, David A., et al.
Publicado: (2012)

The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy
por: Hamilton, Gerhard, et al.
Publicado: (2021)

Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro
por: Lou, Rui, et al.
Publicado: (2019)

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

Metformin mediated microRNA-7 upregulation inhibits growth, migration, and invasion of non-small cell lung cancer A549 cells
por: Dong, Jingying, et al.
Publicado: (2020)

Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients
por: Sajdik, Constantin, et al.
Publicado: (2022)

Rosthorin A inhibits non-small cell lung cancer cell growth and metastasis through repressing epithelial-mesenchymal transition via downregulating Slug
por: Ni, Lulu, et al.
Publicado: (2020)

Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study
por: Illini, Oliver, et al.
Publicado: (2022)

Interactions of BRCA1-mutated Breast Cancer Cell Lines with Adipose-derived Stromal Cells (ADSCs)
por: Plangger, Adelina, et al.
Publicado: (2021)

Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells
por: Zhou, Jianwen, et al.
Publicado: (2019)

Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
por: Hochmair, Maximilian
Publicado: (2018)

The role of oxidative stress in 63 T-induced cytotoxicity against human lung cancer and normal lung fibroblast cell lines
por: Kucinska, Malgorzata, et al.
Publicado: (2018)

Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer
por: Kriegshäuser, Gernot, et al.
Publicado: (2011)

The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
por: Buder, Anna, et al.
Publicado: (2020)

EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
por: Buder, Anna, et al.
Publicado: (2020)

Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series
por: Hochmair, Maximilian Johannes, et al.
Publicado: (2022)

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
por: Luo, Fan, et al.
Publicado: (2019)

In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines
por: Klameth, Lukas, et al.
Publicado: (2017)

Small cell lung cancer.
por: Leonard, R. C.
Publicado: (1989)

Inhibitory Effects of Salinomycin on Cell Survival, Colony Growth, Migration, and Invasion of Human Non-Small Cell Lung Cancer A549 and LNM35: Involvement of NAG-1
por: Arafat, Kholoud, et al.
Publicado: (2013)

Effects of metformin on human bone-derived mesenchymal stromal cell—breast cancer cell line interactions
por: Teufelsbauer, Maryana, et al.
Publicado: (2022)

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
por: Manegold, Christian, et al.
Publicado: (2012)

Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
por: Zhang, Na, et al.
Publicado: (2020)

Cytotoxic Effects of Fascaplysin against Small Cell Lung Cancer Cell Lines
por: Hamilton, Gerhard
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ujcfvou7uamvbk4r8jgr5a9vrq